Compare LTBR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTBR | DRTS |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 125 |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 575.6M | 546.5M |
| IPO Year | 2015 | N/A |
| Metric | LTBR | DRTS |
|---|---|---|
| Price | $10.72 | $6.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | ★ 776.0K | 227.4K |
| Earning Date | 05-11-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.10 | $2.30 |
| 52 Week High | $31.34 | $8.60 |
| Indicator | LTBR | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 45.05 |
| Support Level | N/A | $6.37 |
| Resistance Level | $15.48 | $7.75 |
| Average True Range (ATR) | 0.61 | 0.42 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 28.57 | 25.00 |
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.